Loading patent…
AssigneeBoehringer Ingelheim International GmbH
InventorsPatrick BAUM, Mary Ruth FLACK, Annette Bettina GALLER, Bojan LALOVIC, Kaori MAINO, Steven John PADULA, Paul SCHOLL, Koji SHA, Sudha VISVANATHAN, Patrick GARIDEL, Torsten SCHULTZ-FADEMRECHT
Estimating the term…
This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis or psoriatic arthritis, utilizing anti-IL-23A antibodies. Also disclosed herein are formulations comprising anti-IL-23p19 antibodies, such as risankizumab, which bind the p19 subunit of human IL-23. More specifically, pharmaceutical formulations comprising a high concentration of the anti-IL-23p19 antibody risankizumab, as well as related products and uses for the treatment of various diseases and disorders, are disclosed.
A method for treating psoriasis, said method comprising administering Antibody A to a patient previously treated with a first agent, wherein the PASI score or sPGA score of said patient improves after the administration of Antibody A.
A stable liquid aqueous pharmaceutical formulation, comprising:
A method for treating psoriasis, said method comprising administering a stable liquid aqueous pharmaceutical formulation to a patient previously treated with a first agent, wherein the stable liquid aqueous pharmaceutical formulation comprises:
Dependencies are inferred from the claim text.